Clinical trials: Antipsychotic Agents
Schizophrenia
CATIE- Schizophrenia Trial
The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of…
- Trial name
- NCT00014001
- Testing
- perphenazine, olanzapine, quetiapine
- Where
- 54 sites in United States
- Volunteers
- 1,600 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia
This study is being conducted to find a way to predict how individual schizophrenic patients will respond if they are treated with different types of antipsychotic drugs.
- Trial name
- BEST (NCT00712270)
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Kettering Health Network
Schizophrenia, Schizoaffective Disorder
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
The study attempts to evaluate a histamine analog long used for the treatment of Meniere's disease, betahistine, that shows promise in reversing the antihistaminergic effects thought to be involved in antipsychotic induced weight…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder
- Trial name
- NCT00709202
- Testing
- Betahistine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Major Depressive Disorder
Oral Multiple-dose Study in Patients With Major Depressive Disorder
A study was to evaluate the safety and plasma concentration changes of quetiapine after repeated administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive disorder (MDD).
- Trial name
- NCT01924520
- Testing
- FK949E
- Where
- 2 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Astellas Pharma Inc
Schizophrenia, Schizophrenia Relapse
Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
This prospective longitudinal cohort study will follow patients with schizophrenia who are treated with second generation long-acting injectable antipsychotic medications (LAIs) for 48 weeks to determine the risk of psychotic…
- Trial name
- NCT05473741
- Testing
- Second Generation Long-Acting Injectable Antipsychotic Medications
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in Schizophrenia
The objective of the study is to evaluate the influence of vitamin D supplementation on Serum Brain Derived Neurotrophic Factor level and cognitive function in schizophrenia treated with atypical antipsychotic.
- Trial name
- NCT03284294
- Testing
- Cholecalciferol
- Volunteers
- 40 people
- Sponsor
- Universitas Padjadjaran
Schizophrenia
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
The purpose of this study was to evaluate the efficacy of ASP4345 on cognitive impairment compared to placebo using change from baseline in MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite score (excluding…
- Trial name
- NCT03557931
- Testing
- ASP4345, risperidone, quetiapine
- Where
- 27 sites in United States
- Volunteers
- 233 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Schizophrenia
Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia
Efficacy and safety of Tandospirone combined with Atypical Antipsychotic drugs to Improve Cognitive function in Schizophrenia
- Trial name
- TAAS (NCT02040883)
- Testing
- Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole, Tandospirone
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qingyun Yin
Schizophrenia Spectrum, Schizophrenia
The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. There are no hitherto effective treatments for reducing antipsychotic-induced weight gain.
- Conditions
- Schizophrenia Spectrum, Schizophrenia, Antipsychotic Induced Weight Gain
- Trial name
- dTMS (NCT07795554)
- Testing
- dTMS of accelerated intermittent theta burst stimulation, ACC-iTBS
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Xiangya Hospital of Central South University
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P versus placebo in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.
- Trial name
- NCT04421456
- Testing
- GWP42003-P
- Where
- 39 sites in United States, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Jazz Pharmaceuticals
Healthy
Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo
The purpose of this pilot randomized clinical trial is to begin to delineate the pathophysiological changes associated with antipsychotic associated metabolic side effects.
- Trial name
- NCT01920802
- Testing
- olanzapine, iloperidone
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Alzheimer's Disease, Schizophrenia
Optimisation of Antipsychotic Drug Use in Older People
Drugs such as amisulpride, known as antipsychotic drugs, are used to treat troublesome and distressing symptoms in older people.
- Trial name
- NCT01454453
- Testing
- Patients- dose titration
- Where
- United Kingdom
- Volunteers
- 64 people
- Sponsor
- Institute of Psychiatry, London
Schizophrenia
A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose
The purposes of this study are to investigate the metabolic pathways of paliperidone and excretion of paliperidone and its metabolites in healthy adult male volunteers, both CYP2D6 poor and extensive metabolizers, after…
- Trial name
- NCT00796029
- Testing
- 14C-paliperidone
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
The aberrant expression of micro-RNAs (miRNAs) has been described in many human diseases, including schizophrenia (SZ). The previous work has indicated a strong genetic association between the miRNA-30e precursor (pre-miR-30e)…
- Trial name
- NCT02650102
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shanxi Medical University
Mental Health, Psychotic Disorders
Monitoring and Management for Metabolic Side Effects of Antipsychotics
The purpose of this study is to test an approach for implementing guideline recommendations for assessing and managing metabolic side effects (including weight gain, diabetes, elevated lipids) in patients prescribed antipsychotic…
- Trial name
- AMMP (NCT01875861)
- Testing
- Evidence-Based Quality Improvement Plus Facilitation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months.
- Trial name
- NCT00373672
- Testing
- armodafinil (Nuvigil)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Northwestern University
Akathisia, Drug-Induced, Antipsychotic Agents
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
This study is designed to evaluate the effectiveness of preladenant in the prevention (Part 1) or treatment (Part 2) of antipsychotic induced akathisia in participants with acute psychosis using the Barnes Akathisia Scale.
- Conditions
- Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders
- Trial name
- NCT00693472
- Testing
- Preladenant, Anticholinergic agents or propanolol, Haloperidol
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Safety and Efficacy of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01625000
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 512 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia, Schizoaffective Disorder
Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
Because ziprasidone has not been extensively studied and is not widely accepted in the severely mentally ill in State hospitals this study aims to demonstrate its effectiveness and relative lack of side effects.
- Trial name
- NCT00458211
- Testing
- ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bronx Psychiatric Center